

NCT01850524: Phase 3 - TOURMALINE-MM2 - Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex NDMM
TOURMALINE-MM2 IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With...
Dec 6, 2013
138


NCT01665794: Phase 1/2: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With RRMM
NCT01665794: Phase 1/2: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma...
Dec 21, 2012
167


NCT01568866: Phase 3 - Carfilzomib and Dex Vs Bortezomib & Dex for Relapsed Myeloma (ENDEAVOR)
The ENDEAVOR Trial KD Vs Vd The primary objective of this study was to compare progression-free survival in patients with multiple...
Dec 12, 2012
476


NCT01454297: MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma - (CoMMpass)
MMRF CoMMpass Study Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass) The primary...
Dec 9, 2011
868


NCT01239797: Phase 3: Lenalidomide and Dexamethasone With or Without Elotuzumab RRMM (ELOQUENT - 2)
ELOQUENT - 2 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple...
Dec 18, 2010
102


NCT01080391: Comparing Carfilzomib, Lenalidomide & Dex (CRd) vs Lenalidomide and Dex (Rd) - ASPIRE
THE ASPIRE TRIAL Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in...
Dec 10, 2010
547


NCT01023308: Phase 3 - Panobinostat or Placebo With Bortezomib & Dex in Relapsed Myeloma PANORAMA-1
PANORAMA Panobinostat (LBH589) is a highly potent pan-deacetylase inhibitor (pan-DACi), inclusive of HDAC6, which disrupts aggresome...
Dec 12, 2009
246


NCT00689936: Phase 3 - Lenalidomide+low dose dex vs Melphalan, Prednisone, Thalidomide in NDMM FIRST
FIRST study IFM 07-01 CC-5013-MM020 Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan,...
Dec 14, 2008
442


NCT00609167: Phase 2: Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With NDMM
NCT00609167: Phase 2: Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma...
Dec 3, 2008
68


NCT00511238: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
RRMM Relapsed and Refractory Multiple Myeloma NCT00511238: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma...
Dec 14, 2007
91


NCT00473590: Phase 2 - Bevacizumab in Combination With Bortezomib in MM (AMBER)
NCT00473590: Phase 2: A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma...
Dec 7, 2007
241


NCT00056160 : Phase 3 - CC-5013 (lenalidomide) Dex Vs Dex Alone Previously Treated Multiple Myeloma
Multiple Myeloma (009) MM-009 NCT00056160 : Phase 3 - CC-5013 Plus Dex Versus Dex Alone in Previously Treated Subjects With Multiple...
Dec 11, 2003
153